Human papillomavirus infection (HPV) and pregnancy

1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine, 2012;30 Suppl 5:F12–23.
2. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer, 2009;124(7):1626–1636.
3. Chaitanya NC, Allam NS, Gandhi Babu DB, et al. Systematic meta-analysis on association of human papilloma virus and oral cancer. J Cancer Res Ther, 2016;12(2):969–974.
4. Ellington TD, Henley SJ, Senkomago V, O’Neil ME, et al. Trends in Incidence of Cancers of the Oral Cavity and Pharynx – United States 2007–2016. MMWR Morb Mortal Wkly Rep, 69(15):433– 438.
5. Tachezy R, Klozar J, Rubenstein L, et al. Demographic and risk factors in patients with head and neck tumors. J Med Virol, 2009;81(5):878–887.
6. Gillison ML, Alemany L, Snijders PJ, et al. Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Resipiratory Papillomatosis. Vaccine, 2012;30S:F34–F54.
7. Dyrhonová M, Chlíbek R. Pandemie infekce virem hepatitiy C.Epidemiol Mikrobiol Imunol, 2016;65(2):72–78.
8. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology, 2010;401(1):70–79.
9. Condrat CE, Filip L, Gherghe M, et al. Maternal HPV Infection: Effects on Pregnancy Outcome. Viruses, 2021;13:2455.
10. Bzhalava D., Eklund C., Dillner J. International standardization and classification of human papillomaviruses types, Virology, 2015; 476: 341–344.
11. Asgari MM, Ray GT, Quesenberry CP Jr, et al. Association of Multiple Primary Skin CancersWith Human Immunodeficiency Virus Infection, CD4 Count, and Viral Load. JAMA Dermatol, 2017;153:892–896.
12. International HPV Reference Center, Karolinska Universitetssjukhuset. Dostupné na www: https://www.hpvcenter.se/hu- man_reference_clones/.
13. Giuliano AR, Nyitray AG, Kreimer AR, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus –related cancer incidence by gender and anatomic site of infection. Int J Cancer, 2015;136(12): 2752–2760.
14. Sehnal B, Rozsypal H, Nipčová M, Sláma J. Prevalence, incidence, perzistence a možnosti přenosu infekce lidským papilomavirem (HPV). Epidemiol Mikrobiol Imunol, 2017; 66(4):198–209.
15. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens – Part B: biological agents. Lancet Oncol, 2009;10(4):321–322.
16. Værnesbranden MR, Wiik J, Sjøborg K, et al. Maternal human papillomavirus infections at mid-pregnancy and delivery in a Scandinavian mother-child cohort study. Int. J. Infect. Dis, 2021;108:574–581.
17. Liu P, Xu L, Sun Y, Wang Z. The prevalence and risk of human papillomavirus infection in pregnant women. Epidemiol Infect, 2014;142(8):1567–1578.
18. Luo D, Peng M, Wei X, et al. Prevalence of Human Papillomavirus and Genotype Distribution in Pregnant and Non-Pregnant Women in China. Risk Manag. Healthc. Policy, 2021;14:3147– 3157.
19. Ardekani A, Sepidarkish M, Mollalo A, et al. Worldwide prevalence of human papillomavirus among pregnant women: A systematic review and meta-analysis. Rev Med Virol, 2023;33(1):e2374.
20. Chen SS, Block BS, Chan PJ. Pentoxifylline attenuates HPV-16 associated necrosis in placental trophoblasts. Arch Gynecol Obstet, 2015;291:647e5.
21. Hermonat PL, Han L, Wendel PJ, et al. Human papillomavirus is more prevalent in first trimester spontaneously aborted products of conception compared to elective specimens. Virus Genes, 1997;14:13–17.
22. Slatter TL, Hung NG, Clow WM, et al. A clinicopathological study of episomal papillomavirus infection of the human placenta and pregnancy complications. Mod Pathol, 2015;28:1369e82.
23. Ambühl LMM, Leonhard AK, Widen Zakhary C, et al. Human papillomavirus infects placental trophoblast and Hofbauer cells, but appears not to play a causal role in miscarriage and preterm labor. Acta Obstet Gynecol Scand, 2017;96:1188e96
24. You H, Liu Y, Carey MJ, et al. Defective 3A trophoblast-endometrial cell adhesion and altered 3A growth and survival by human papillomavirus type 16 oncogenes. Mol Cancer Res, 2002;1:25– 31.
25. Boulenouar S, Weyn C, Van Noppen M, et al. Effects of HPV-16 E5, E6 and E7 proteins on survival, adhesion, migration and invasion of trophoblastic cells. Carcinogenesis, 2010;31:473–480.
26. Reiter PL, Pendergraft WF, 3rd, Brewer NT. Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev, 2010;19:2916–2931.
27. Rob F, Tachezy R, Pichlík T, et al. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys. Dermatol Ther, 2017;30(1). doi: 10.1111/ dth.12435.
28. Rombaldi RL, Serafini EP, Mandelli J, et al. Perinatal transmission of human papilomavirus DNA. Virol J, 2009;6:83.
29. Sarkola ME, Grenman SE, Rintala MA, Syrjänen KJ, Syrjänen SM. Human papillomavirus in the placenta and umbilical cord blood. Acta Obstet Gynecol Scand, 2008; 87:1181e8.
30. Çağlar GS, Garrido N. The implications of male human papilloma virus infection in couples seeking assisted reproduction technologies. Journal of the Turkish German Gynecological Association, 2018;19:48–52.
31. Zákon č. 372/2011 Sb., o zdravotních službách a podmínkách jejich poskytování. Dostupné na www: https://ppropo.mpsv.cz/ zakon_372_2011.
32. Yang J, Chen M, Ye X, et al. A cross-sectional survey of pregnant women’s knowledge of chromosomal aneuploidy and microdeletion and microduplication syndromes. Eur J Obstet Gynecol Reprod Biol, 2021;256:82–90.
33. Bober L, Guzowski G, Moczulska H, et al. Influence of human Papilloma Virus (hPV) infection on early pregnancy. Ginekol Pol, 2019;90:72–75.
34. Conde-Ferráez L, May ADAC, Carrillo-Martínez JR, et al. Human papillomavirus infection and spontaneous abortion: A case-control study performed in Mexico. Eur J Obstet Gynecol Reprod Biol, 2013;170:468–473.
35. Ticconi C, Pietropolli A, Fabbri G, et al. Recurrent miscarriage and cervical human papillomavirus infection. Am J Reprod Immunol, 2013;70:343–346.
36. Skoczyński M, Goździcka-Józefiak A, Kwaśniewska A. Prevalence of human papillomavirus in spontaneously aborted products of conception. Acta Obstet Gynecol Scand, 2011;90(12):1402– 1405.
37. Xiong Y Q, Mo Y, Luo QM, et al. The Risk of Human Papillomavirus Infection for Spontaneous Abortion, Spontaneous Preterm Birth, and Pregnancy Rate of Assisted Reproductive Technologies: A Systematic Review and Meta-Analysis. Gynecol Obstet Investig, 2018;83:417–427.
38. Česká gynekologická a porodnická společnost (ČGPS) České lékařské společnosti Jana Evangelisty Purkyně (ČLS JEP). Dostupné na www: https://gynultrazvuk.cz/doporucene-postupy.
39. Český statistický úřad (ČSÚ). Dostupné na www: https://www. czso.cz/csu/czso/podil-predcasne-narozenych-deti-klesa.
40. Romero R, Mazor M. Infection and preterm labor. Clinical obstetrics and gynekology, 1988;31:553–584. doi:10.1097/00003081790 198809000-00006.
41. Cotton-Caballero A, Dudley D, Ferguson J, et al. Maternal Human Papillomavirus Infection Increases the Risk of Premature Rupture of Membranes [19M]. Obstet Gynecol, 2017;129:S137.
42. Niyibizi J, Mayrand MH, Audibert F, et al. Association Between Human Papillomavirus Infection Among Pregnant Women and Preterm Birth. JAMA Network Open, 2021;4:e2125308.
43. McDonnold M, Dunn H, Hester A, et al. High risk human papillomavirus at entry to prenatal care and risk of preeclampsia. Am J Obstet Gynecol, 2014;210:138.e1–138.e5.
44. Mosbah A, Barakat R, Nabiel Y, et al. High-risk and low-risk human papilloma virus in association to spontaneous preterm labor: A case-control study in a tertiary center, Egypt. J Matern Fetal Neonatal Med, 2018;31:720–725.
45. Cho G, Min KJ, Hong HR, et al. High-risk human papillomavirus infection is associated with premature rupture of membranes. BMC Pregnancy Childbirth, 2013;13:173.
46. Pandey D, Solleti V, Jain G, et al. Human Papillomavirus (HPV) Infection in Early Pregnancy: Prevalence and Implications. Infect Dis Obstet Gynecol, 2019;2019:4376902
47. Aldhous MC, Bhatia R, Pollock R, et al. HPV infection and preterm birth: A data-linkage study using Scottish Health Data. Wellcome Open Res, 2019;4:48.
48. Subramaniam A, Lees BF, Becker DA, et al. Evaluation of Human Papillomavirus as a Risk Factor for Preterm Birth or Pregnancy-Related Hypertension. Obstet. Gynecol, 2016; 127:233–240.
49. Huang QT, Zhong M, Gao YF, et al. Can HPV vaccine have other health benefits more than cancer prevention? A systematic review of association between cervical HPV infection and preterm birth. J Clin Virol, 2014;61:321–328.
50. Niyibizi J, Zanré N, Mayrand MH, et al. Association Between Maternal Human Papillomavirus Infection and Adverse Pregnancy Outcomes: Systematic Review and Meta-Analysis. J Infect Dis, 2020;221:1925–1937.
51. Wu D, Chen L, Zhen J, et al. Systematic review and meta-analysis on influence of human papillomavirus infection during pregnancy on premature rupture of membranes and premature delivery. Ann Palliat Med, 2021;10:10735–70743.
52. Wiik J, Nilsson S, Kärrberg C, et al. Associations of treated and untreated human papillomavirus infection with preterm delivery and neonatal mortality: A Swedish population – based study. PLoS Med, 2021;18:e1003641.
53. Vlk R. Preeklampsie – od patofyziologie ke klinické praxi. Maxdorf; 2015. s. 46-122, s. 165–177. ISBN: 978-80-7345-460-9.
54. Sharma D, Shastri S, Sharma P. Intrauterine Growth Restriction: Antenatal and Postnatal Aspects. Clin Med Insights Pediatr, 2016;10:67–83.
55. Reily-Bell AL, Fisher A, Harrison B, et al. Human Papillomavirus E6/E7 Expression in Preeclampsia-Affected Placentae. Pathogens, 2020;9(3):239.
56. Karowicz-Bilińska A. The latent infection of human papilloma virus in pregnat woman and colonization of placenta – preliminary report. Ginekol Pol, 2007;78(12):966–970.
57. Ford JH. Preconception risk factors and SGA babies: Papilloma virus, omega 3 and fat soluble vitamin deficiencies. Early Human Development, 2011;87(12):785–789.
58. Ford JH, Li M, Scheil W, et al. Human papillomavirus infection and intrauterine growth restriction: A data-linkage study. J Matern.-Fetal Neonatal Med, 2019;32:279–285.
59. Kuehn BM. Pandemic Contributes to Worse Pregnancy Outcomes Worldwide. JAMA, 2021;325:1931.
60. World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017 – Recommendations. Vaccine, 2017;35:5753–5755.
61. Bonde U, Joergensen JS, Lamont RF, et al. Is HPV vaccination in pregnancy safe? Hum Vaccin Immunother, 2016;12:1960–1964.
62. Wacholder S, Chen BE,Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ, 2010;340:c712.
63. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol, 2009;114:1170–1178.
64. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol, 2009;114:1179–1188.
65. Moto PL, Zheteyeva Y, Lewis P, et al. Safety of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Pregnancy: Review of Non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006 – 2013. Vaccine, 2015;33(4):519–522.
66. Kharbanda EO, Vazquez-Benitez G, DeSilva MB, et al. Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes. JAMA Netw Open, 2021;4(4):e214340.
67. Wang A, Liu C, Wang Y, et al. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis. Hum Vaccin Immunother, 2020;16(3):581–589.
68. Etti M, Calvert A, Galiza E, et al. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol, 2021:S0002–9378(21)01228-X.
69. Tempfer C. Vaccinations for pregnant women and women attempting to become pregnant. Gynakol Endokrinol, 2022:1–8.
70. Rintala MA, Grénman SE, Järvenkylä ME, et al. High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: Experience from the Finnish HPV Family Study. Clin. Infect. Dis, 2005;41:1728–1733.
71. Niyibizi J, Zanré N, Mayrand MH, et al. The association between adverse pregnancy outcomes and maternal human papillomavirus infection: A systematic review protocol. Syst. Rev, 2017;6:53.
72. Yuan S, Qiu Y, Xu Y, et al. Human papillomavirus infection and female infertility: a systematic review and meta-analysis. Reprod Biomed Online, 2020;40(2):229–237.
73. Yuill S, Egger S, Smith M, et al. Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. J Infect Dis, 2020;222:499–508.
74. Kalliala I, Eriksson T, Aro K, et al. Preterm birth rate after bivalent HPV vaccination: Registry-based follow-up of a randomized clinical trial. Prev Med, 2021;146:106473.
75. Marshall H, McMillan M, Andrews RM, et al. Vaccines in pregnancy: The dual benefit for pregnant women and infants. Hum. Vaccin. Immunother., 2016;12:848–856.
76. Eckert LON. Human Papillomavirus Vaccination: ACOG Committee Opinion Summary, Number 809. Obstet. Gynecol., 2020;136:E15–E21.
77. Munoz FM, Eckert LO, Katz MA, et al. Key terms for the assessment of the safety of vaccines in pregnancy: Results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine, 2015;33(47):6441–6452.

Grantová podpora

Projekt Národního institutu virologie a bakteriologie (Program EXCELES, ID: LX22NPO5103) – financováno Evropskou unií – Next Generation EU.
Cooperatio program, Maternal and Childhood Care No. 207035,
3. lékařská fakulta Karlovy Univerzity.

Do redakce došlo dne 17. 8. 2023.

Adresa pro korespondenci:
as. MUDr. Borek Sehnal, Ph.D.
Gynekologicko-porodnická klinika
Fakultní nemocnice Královské Vinohrady
Šrobárova 1150/50 100 34 Praha 10
e-mail: boreksehnal@seznam.cz